{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.0","value":"94.5"},{"groupId":"OG001","spread":"16.7","value":"95.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"248"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.1","value":"94.1"},{"groupId":"OG001","spread":"15.5","value":"92.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"title":"6 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"93.4"},{"groupId":"OG001","spread":"16.2","value":"90.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"18 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"95.7"},{"groupId":"OG001","spread":"15.7","value":"94.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"title":"30 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.2","value":"93.5"},{"groupId":"OG001","spread":"15.0","value":"96.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"title":"54 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"248"}],"units":"Participants"}],"description":"QoL are collected in pMMR patients only and measured with the Function Assessment of Cancer Therapy -Endometrial Trial Outcome Index (FACT En-TOI). The FACT-En TOI scores range 0 - 120 with a larger score suggesting better or favorable state of QOL.","dispersionType":"Standard Deviation","groups":[{"description":"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"(pMMR Cohort): Arm 1: Active Comparator (Placebo, Paclitaxel, Carboplatin)"},{"description":"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"(pMMR Cohort): Arm 2: Experimental (Pembrolizumab, Paclitaxel, Carboplatin)"}],"paramType":"MEAN","populationDescription":"The pMMR patients who provided baseline and at least one follow-up QOL assessment.","reportingStatus":"POSTED","timeFrame":"0-54 weeks from start of treatment","title":"Quality of Life (QoL) in pMMR Patients Only","type":"SECONDARY","unitOfMeasure":"score"}